Richard Baird
Richard Baird
Cancer Research UK Cambridge Centre
Verified email at - Homepage
Cited by
Cited by
Liquid biopsies come of age: towards implementation of circulating tumour DNA
JCM Wan, C Massie, J Garcia-Corbacho, F Mouliere, JD Brenton, ...
Nature Reviews Cancer 17 (4), 223-238, 2017
Enhanced detection of circulating tumor DNA by fragment size analysis
F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ...
Science translational medicine 10 (466), eaat4921, 2018
The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
SK Sandhu, WR Schelman, G Wilding, V Moreno, RD Baird, S Miranda, ...
The lancet oncology 14 (9), 882-892, 2013
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors
TA Yap, LI Yan, A Patnaik, I Fearen, D Olmos, K Papadopoulos, RD Baird, ...
Journal of clinical oncology 29 (35), 4688-4695, 2011
A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds
A Bruna, OM Rueda, W Greenwood, AS Batra, M Callari, RN Batra, ...
Cell 167 (1), 260-274. e22, 2016
First-in-human phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors
D Sarker, JE Ang, R Baird, R Kristeleit, K Shah, V Moreno, PA Clarke, ...
Clinical cancer research 21 (1), 77-86, 2015
Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial
P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ...
Journal of Clinical Oncology 38 (5), 423-433, 2020
Clinical development of new drug–radiotherapy combinations
RA Sharma, R Plummer, JK Stock, TA Greenhalgh, O Ataman, S Kelly, ...
Nature reviews Clinical oncology 13 (10), 627-642, 2016
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
NC Turner, B Kingston, LS Kilburn, S Kernaghan, AM Wardley, ...
The Lancet Oncology 21 (10), 1296-1308, 2020
Drug resistance reversal—are we getting closer?
RD Baird, SB Kaye
European Journal of Cancer 39 (17), 2450-2461, 2003
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot, RH Jones, H Eng, ...
Molecular cancer 22 (1), 138, 2023
Imaging breast cancer using hyperpolarized carbon-13 MRI
FA Gallagher, R Woitek, MA McLean, AB Gill, R Manzano Garcia, ...
Proceedings of the National Academy of Sciences 117 (4), 2092-2098, 2020
Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
AW Tolcher, K Khan, M Ong, U Banerji, V Papadimitrakopoulou, ...
Clinical Cancer Research 21 (4), 739-748, 2015
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with …
B Venugopal, R Baird, RS Kristeleit, R Plummer, R Cowan, A Stewart, ...
Clinical Cancer Research 19 (15), 4262-4272, 2013
Weekly paclitaxel in the treatment of recurrent ovarian cancer
RD Baird, DSP Tan, SB Kaye
Nature reviews Clinical oncology 7 (10), 575-582, 2010
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ...
Annals of Oncology 30 (5), 766-773, 2019
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2 Advanced Breast Cancer
EP Hamilton, MR Patel, AC Armstrong, RD Baird, K Jhaveri, M Hoch, ...
Clinical Cancer Research 24 (15), 3510-3518, 2018
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
TA Yap, L Yan, A Patnaik, N Tunariu, A Biondo, I Fearen, ...
Clinical cancer research 20 (22), 5672-5685, 2014
Genetic heterogeneity in breast cancer: the road to personalized medicine?
RD Baird, C Caldas
BMC medicine 11, 1-5, 2013
AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled …
P Schmid, J Abraham, S Chan, D Wheatley, M Brunt, G Nemsadze, ...
J Clin Oncol 36 (15_suppl), 1007, 2018
The system can't perform the operation now. Try again later.
Articles 1–20